5 Key Takeaways
-
1
New data at ARVO 2025 supports combining PRAME status with the DecisionDx-UM test for better metastatic risk prediction in uveal melanoma.
-
2
The analysis included 1,297 patients, marking the first independent real-world validation of the 2023 COOG2.1 study.
-
3
PRAME gene expression enhances metastatic risk stratification, distinguishing between Class 1 and Class 2 tumors.
-
4
Three-year melanoma-specific survival rates varied significantly based on PRAME status and tumor class.
-
5
Castle Biosciences plans to further evaluate the combined biomarker approach as additional follow-up data becomes available.
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.